Citadel Advisors
CLRB icon

Citadel Advisors’s Cellectar Biosciences CLRB Stock Holding History

Citadel Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-610
Closed -$5.77K – 12799
2025
Q1 		$5.77K Buy
610
+290
+91% +$2.63K ﹤0.01% 13793
2024
Q4 		$2.87K Sell
320
-807
-72% -$37.3K ﹤0.01% 14045
2024
Q3 		$72.3K Buy
1,127
+170
+18% +$11.2K ﹤0.01% 11513
2024
Q2 		$71.8K Sell
957
-966
-50% -$92.7K ﹤0.01% 11347
2024
Q1 		$230K Buy
+1,923
New +$208K ﹤0.01% 10039

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's CLRB Position: Q4 2025 in Review

Citadel Advisors sold out of Cellectar Biosciences (CLRB) in Q4 2025, closing a stake of 18,526 shares — an estimated $104K sold.

Citadel Advisors first reported a position in CLRB in Q1 2017 and held it in 17 quarters. The position peaked at $468K in Q1 2024. 20 funds tracked by Wall St. Rank hold CLRB as of Q4 2025.

  • Citadel Advisors reported no remaining Cellectar Biosciences position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 18,526 Cellectar Biosciences shares in Q4 2025, an estimated $104K.
  • Citadel Advisors first reported a position in Cellectar Biosciences in Q1 2017 and held it in 17 quarters.
  • Citadel Advisors's Cellectar Biosciences position peaked at $468K in Q1 2024.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.